Seventy-five STEMI patients who had received emergency reperfusion therapy were enrolled and randomized into the hydrophilic statin group ( rosuvastatin ; 5 mg/day , n = 38 ) and hydrophobic statin group ( atorvastatin ; 10 mg/day , n = 37 ) for 6 months .